Related references
Note: Only part of the references are listed.Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study
Ballari Brahmachari et al.
INDIAN JOURNAL OF PHARMACOLOGY (2011)
F-18-FPPRGD2 and F-18-FDG PET of Response to Abraxane Therapy
Xilin Sun et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel
Fausto Petrelli et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Cytoskeletal Disassembly and Cell Rounding Promotes Adipogenesis from ES Cells
Tianshu Feng et al.
STEM CELL REVIEWS AND REPORTS (2010)
Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images
Sheng-Hann Wang et al.
JOURNAL OF NANOBIOTECHNOLOGY (2010)
Abraxane for the Treatment of Gynecologic Cancer Patients With Severe Hypersensitivity Reactions to Paclitaxel
Amanda N. Fader et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Postoperative Chemotherapy After Neoadjuvant Chemoradiation and Surgery for Rectal Cancer: Is it Essential for Patients With ypT0-2N0?
Jung Wook Huh et al.
JOURNAL OF SURGICAL ONCOLOGY (2009)
Therapeutic nanoparticles for drug delivery in cancer
Kwangjae Cho et al.
CLINICAL CANCER RESEARCH (2008)
Radiosensitization of paclitaxel, etanidazole and paclitaxel plus etanidazole nanoparticles on hypoxic human tumor cells in vitro
Cheng Jin et al.
BIOMATERIALS (2007)
Paclitaxel: a review of adverse toxicities and novel delivery strategies
Neena I. Marupudi et al.
EXPERT OPINION ON DRUG SAFETY (2007)
Paclitaxel prodrugs: Toward smarter delivery of anticancer agents
Mariusz Skwarczynski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Paclitaxel-loaded PLGA nanoparticles: Potentiation of anticancer activity by surface conjugation with wheat germ agglutinin
Y Mo et al.
JOURNAL OF CONTROLLED RELEASE (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
JS Kloover et al.
BRITISH JOURNAL OF CANCER (2004)
Drug delivery and transport to solid tumors
SH Jang et al.
PHARMACEUTICAL RESEARCH (2003)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Biology of nitric oxide signaling
L Liaudet et al.
CRITICAL CARE MEDICINE (2000)
Share Paper
